The price of success: Cost-effectiveness of molecularly targeted agents
Clinical Pharmacology and Therapeutics , Volume 85 - Issue 2 p. 136- 138
The advent of molecularly targeted agents has brought major breakthroughs in oncology. However, because these drugs are expensive and financial resources are limited, attention to their cost-effectiveness is rapidly increasing. It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs.
|Clinical Pharmacology and Therapeutics|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Sleijfer, S, & Verweij, J. (2009). The price of success: Cost-effectiveness of molecularly targeted agents. Clinical Pharmacology and Therapeutics (Vol. 85, pp. 136–138). doi:10.1038/clpt.2008.245